RP-7214

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRP-7214
Drug Alias NameRP-7214
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRhizen Pharmaceuticals Sa
China Registration ClassN/A

Develop Information

Active CompaniesRhizen Pharmaceuticals Sa
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A